{"id":"W4392853633","doi":"10.1136/lupus-2024-el.42","title":"O33 Longitudinal assessment of biomarkers in NOBILITY, a randomized, phase II clinical trial of obinutuzumab for treatment of proliferative lupus nephritis","year":2024,"lang":"en","type":"article","venue":"Oral Presentations","topic":"Systemic Lupus Erythematosus Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"Genentech; F. Hoffmann-La Roche; AstraZeneca; Bristol-Myers Squibb","keywords":"Obinutuzumab; Lupus nephritis; Medicine; Internal medicine; Oncology; Disease; Rituximab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001611243,0.0001604354,0.001376663,0.0003732605,0.00003822446,0.00001373414,0.00009379163,0.000105899,0.0001034828],"category_scores_gemma":[0.0008664101,0.0001176917,0.0006138845,0.0004634762,0.0004739801,0.0001088277,0.00005090577,0.00008508654,0.000001066294],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002921814,"about_ca_system_score_gemma":0.001373596,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005847173,"about_ca_topic_score_gemma":0.0001811458,"domain_scores_codex":[0.996745,0.0005786511,0.001621258,0.0003563816,0.0004821986,0.0002164768],"domain_scores_gemma":[0.9963977,0.00258467,0.000240105,0.0003365909,0.000337025,0.0001038481],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8715161,0.01218673,0.08234809,0.00346953,0.004654546,0.00008029797,0.004973596,0.00004632367,0.003362364,0.003586345,0.002781105,0.01099497],"study_design_scores_gemma":[0.962752,0.01208089,0.0004916668,0.0006718485,0.0006905757,0.000189385,0.001168596,0.01866356,0.002358987,0.0006400741,0.0001856573,0.0001066926],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9842395,0.0006037772,0.002422111,0.0005535876,0.0005464273,0.0104895,0.0002484753,0.00001952076,0.0008771021],"genre_scores_gemma":[0.9928118,0.0002203329,0.004399011,0.00000277359,0.0001160835,0.001668299,0.000123519,0.0000202771,0.000637881],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09123596,"threshold_uncertainty_score":0.4799328,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1512239871831306,"score_gpt":0.5173853706958021,"score_spread":0.3661613835126716,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}